




Contents lists available at ScienceDirect

Journal of Clinical Neuroscience

journal homepage: www.elsevier.com/locate/jocn

Clinical Study

Influence on morbidity and mortality of neoadjuvant radiation and chemotherapy among cranial malignancy patients in the postoperative setting



Paul Narayan Hein^b, Bryan Lieber^{b,c}, Eliza Bruce^{a,c}, Blake Taylor^{a,c,d,*}, Geoffrey Appelboom^{a,c}, Mickey Abraham^c, E. Sander Connolly Jr.^{a,c,e}

^a Department of Neurosurgery, Columbia University Medical Center, Physicians and Surgeons Building Room 5-454, 630 West 168th Street, New York, NY 10032, USA

^b Department of Neurosurgery, New York University, New York, NY, USA

^c Cerebrovascular Research Laboratory, Columbia University, New York, NY, USA

^d College of Physicians and Surgeons, Columbia University, New York, NY, USA

^e Neuro-Intensive Care Unit, Columbia University Medical Center, New York, NY, USA

ARTICLE INFO

Article history:

Received 6 January 2015

Accepted 10 January 2015

Keywords:

30 day outcomes

Chemotherapy

Malignancy

National Surgical Quality Improvement Program

Neoadjuvant

Radiation

ABSTRACT

We sought to assess the impact of neoadjuvant therapy on 30 day mortality and morbidity using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP). Chemotherapy and radiotherapy are both often indicated for treatment of cranial or systemic malignancy but can have significant adverse effects in the postsurgical setting. Data from 2006 to 2012 were obtained from the national ACS-NSQIP database. A total of 1044 patients were identified who obtained surgery for removal of metastatic brain tumors, of whom 127 received neoadjuvant chemotherapy and 65 neoadjuvant radiotherapy. Our primary outcome was 30 day mortality and secondary outcomes were 30 day surgical and medical morbidities. We selected previously reported preoperative variables to build a univariate and a multivariate model to determine preoperative characteristics most associated with neurosurgical mortality and morbidity. Our study found that neoadjuvant chemotherapy was associated with a 2.4-fold increase in the risk of 30 day mortality compared to the patient cohort who did not receive chemotherapy ($p = 0.023$). Interestingly, there was no statistically significant increase in overall 30 day surgical or medical morbidity for the chemotherapy group. Neoadjuvant radiotherapy was not associated with an increase in 30 day morbidity or mortality. The significant increase in mortality associated with chemotherapy warrants further investigation, particularly to determine how to best personalize neoadjuvant chemotherapy treatment options to improve surgical outcomes. Neoadjuvant radiotherapy may be safer in terms of short-term postoperative morbidity and mortality.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Over 50% of cranial tumors are extracranial in origin and brain metastases occur in 10–40% of adults with metastatic forms of cancer [9,12]. Approximately 170,000 metastatic brain tumors are diagnosed every year in the USA. Surgical options are limited but when favored are performed for both alleviation of mass effect or complete excision of the tumor. Adjunct treatments prior to surgery can be helpful in disease control and to potentially decrease tumor size, but chemotherapy and radiotherapy both have

significant side effects that may directly lead to postoperative morbidity and mortality.

Neoadjuvant chemotherapy is often indicated in chemosensitive disease [12]. Chemotherapy may be primarily focused on the cranial tumor or the extracranial disease. Surgical treatment for brain metastases can be combined with radiotherapy or chemotherapy depending on the number and location of metastases, the performance score of the patient, the etiology of the original tumor and the extent of extracranial disease. Whole brain radiation therapy (WBRT) is the most common adjuvant treatment to surgery and while most randomized studies have not found an added overall survival benefit, WBRT generally increases local brain control, reduces the need for reoperation and improves patient wellbeing [5,23].

* Corresponding author. Tel.: +1 212 305 4679; fax: +1 212 305 2026.

E-mail address: bet2110@cumc.columbia.edu (B. Taylor).

The long-term outcome status of each of these adjunctive treatments is well characterized by mortality and postsurgical recurrence of disease for a variety of primary neoplasms [2,4,14,17,19]. However, there is a scarcity of short-term data delineating complications from surgery based on types of preoperative treatment. Analyses of adverse events and which adjunct treatments are associated with complications can guide more tactful utilization or guide preventative measures to mitigate the adverse side effects. We seek to fill this gap with a nationally representative database to demonstrate the impact of neoadjuvant chemotherapy and radiation on postoperative morbidity among metastatic cranial disease.

2. Methods

Data from the years 2006 to 2012 were obtained from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. The ACS-NSQIP reports 30 day morbidity and mortality from nearly 400 academic and community hospitals nationwide [7,10], and has a 95% success rate in capturing outcomes on all patients with a >95% inter-rater reliability [18]. Specially trained surgical clinical reviewers prospectively collect data on randomly assigned consenting surgical patients and adhere to strict methods of collection and definitions of variables [6,8]. An important exclusion criterion is patients under age 18. A complete list of inclusion and exclusion criteria are on the ACS-NSQIP website. Neither patient consent nor Institutional Review Board approval was required as NSQIP is a national, de-identified database.

Similar to previous neurosurgical studies that have queried the ACS-NSQIP database [15], all cranial procedures were selected based on NSQIP-utilized current procedural terminology codes: 21137, 21138, 21139, 21175, 21179–21184, 21299 and 61304–62121. Patients with a malignancy were isolated based on primary postoperative diagnostic ICD-9 (International Classification of Diseases, Ninth Revision) codes associated with secondary cranial malignancy (Supp. Table 1).

Our primary outcome was 30 day mortality and secondary outcomes were medical and surgical complications. We used a modified version of the established categorization of morbidity by Kiran et al. [11], as follows: surgical complications are superficial surgical site infection, deep surgical site infection, organ space infection, wound disruption, bleeding requiring transfusion, failure of graft or prosthesis and peripheral nerve injury; medical complications are pneumonia, pulmonary embolism, acute renal failure, stroke, myocardial infarction, sepsis, urinary tract infection, deep venous thrombosis and thrombophlebitis.

Statistical analyses were performed using SPSS Statistics (version 22; IBM Corporation, Armonk, NY, USA). Initially, univariate analyses were performed on patient demographics and salient preoperative variables using the Pearson chi-squared test or Fisher's exact test when appropriate for categorical data. We selected preoperative variables for univariate testing based off of previous work with ACS-NSQIP analysis by Rolston et al. which determined preoperative characteristics most associated with neurosurgical morbidity [15]. Factors in which $p \leq 0.20$ for mortality were entered into our multivariate regression model.

We utilized binary logistic regression with a maximum number of iterations of 20 and significance threshold of $p < 0.05$. Independent predictors of surgical site infections were identified using this model and their odds ratios (OR) and 95% confidence intervals (CI) were presented. We employed listwise deletion for patients missing any of the studied variables. The sample of complete patients for each analysis is reported. We evaluated logistic regression goodness of fit based on the Hosmer–Lemeshow test.

3. Results

We studied 1044 patients with secondary cranial cancer. Demographic data and frequency of comorbidities in our study sample are delineated in Table 1. Neoadjuvant chemotherapy was associated with increased mortality ($p = 0.02$; OR: 2.42; 95% CI: 1.13–5.19; Table 2). In contrast, neoadjuvant radiotherapy was not associated with increased mortality ($p = 0.48$; OR: 0.69; 95% CI: 0.25–1.90). Our model demonstrated proper goodness of fit (χ^2 : 8.65; $p = 0.37$). There was no overall increase in surgical morbidity with either neoadjuvant radiotherapy ($p = 0.85$; OR: 1.09; 95% CI: 0.47) or chemotherapy ($p = 0.61$; OR: 0.838; 95% CI 0.422–1.66). This regression model also had proper goodness of fit (χ^2 : 8.12; $p = 0.42$; Table 3). Similarly, there was no increase in medical morbidity with neoadjuvant chemotherapy ($p = 0.61$; OR: 0.84; 95% CI: 0.42–1.66) or radiotherapy ($p = 0.85$; OR: 1.09; 95% CI: 0.46–2.54; Table 4). This model also had proper goodness of fit (χ^2 : 5.52; $p = 0.70$).

4. Discussion

Using the ACS-NSQIP database to evaluate postoperative morbidity of neoadjuvant chemotherapy and radiation, we found that neoadjuvant chemotherapy was associated with a 2.4-fold increase

Table 1
Cranial malignancy patient cohort characteristics

Characteristic		Patients, n
Total		1044
Age grouped	16–45	125
	>45–80	870
	>80	49
Gender	Female	541
	Male	503
Inpatient/outpatient	Inpatient	1018
	Outpatient	26
Emergency case	No	965
	Yes	79
Dyspnea	No	914
	Moderate	116
	At Rest	14
Ventilator dependent	No	1029
	Yes	15
History of severe COPD	No	939
	Yes	105
Diabetes	None	921
	Non-ID	81
	ID	42
Hypertension requiring medication	No	617
	Yes	427
Impaired sensorium	No	958
	Yes	86
Steroid use for chronic condition	No	765
	Yes	279
Preoperative infection	None	968
	SIRS or >SIRS	76
Open wound/wound infection	No	1017
	Yes	27
CVA/stroke with no neurological deficit	No	1028
	Yes	16
CVA/stroke with neurological deficit	No	1009
	Yes	35
Disseminated cancer	No	405
	Yes	639
Radiotherapy for malignancy in last 90 days	No	979
	Yes	65
Chemotherapy for malignancy in ≤ 30 days preop	No	917
	Yes	127

COPD = chronic obstructive pulmonary disease, CVA = cerebrovascular accident, ID = insulin dependent, SIRS = systemic inflammatory response syndrome.

Download English Version:

<https://daneshyari.com/en/article/3059072>

Download Persian Version:

<https://daneshyari.com/article/3059072>

[Daneshyari.com](https://daneshyari.com)